Ipsen jumps on ADC bandwagon with deal for Sutro’s ROR1-targeting therapy

2024-04-02

抗体药物偶联物并购引进/卖出临床1期

Ipsen added the first antibody-drug conjugate (ADC) to its pipeline through a deal with Sutro Biopharma potentially worth up to $900 million. Mary Jane Hinrichs, head of early development at Ipsen, suggested that Sutro’s STRO-003, which targets the ROR1 tumour antigen, has “best-in-class potential.”

Ipsen will assume responsibility for Phase I preparation activities for STRO-003 as well as all subsequent clinical development and global marketing activities. In return, Sutro is eligible to receive around $90 million in near-term payments, including an equity investment, along with further milestone payments and tiered sales royalties.

Hinrichs noted that STRO-003 utilises Sutro’s site-specific technology to generate a highly stable conjugate, coupled with exatecan payloads, that have shown significant potential in solid tumours. The ADC is in the final stages of preclinical development.

Both Boehringer Ingelheim and Merck & Co. splashed out in 2020 to add ADCs targeting ROR1 to their pipelines. Merck’s asset, gained via the purchase of VelosBio, is currently in mid-stage development, but Boehringer, which added its therapy through the acquisition of NBE-Therapeutics, halted work on the drug last year.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构